PAVmed Free Cash Flow (FCF) History (PAVM)
PAVmed reported −$5.2M in free cash flow for fiscal 2025, an increase of $28.4M from the previous fiscal year, with a free cash flow margin of −7376.06%.
View full PAVmed company overviewPAVmed free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$5.2M | $28.4M | — | −7376.06% |
| 2024 | 2024-12-31 | −$33.6M | $18.7M | — | −1122.17% |
| 2023 | 2023-12-31 | −$52.3M | $20.2M | — | −2132.06% |
| 2022 | 2022-12-31 | −$72.5M | −$30.5M | — | −19237.40% |
| 2021 | 2021-12-31 | −$42.1M | −$20.1M | — | −8412.00% |
| 2020 | 2020-12-31 | −$22.0M | −$8.6M | — | — |
| 2019 | 2019-12-31 | −$13.4M | −$4.6M | — | — |
| 2018 | 2018-12-31 | −$8.8M | −$2.2M | — | — |
| 2017 | 2017-12-31 | −$6.6M | −$2.1M | — | — |
| 2016 | 2016-12-31 | −$4.5M | — | — | — |
PAVmed quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$2.7M | −$1.5M | — | −8109.09% |
| Q1 2026 | 2026-03-31 | −$2.6M | −$1.1M | — | −12009.09% |
| Q4 2025 | 2025-12-31 | −$1.6M | −$1.7M | — | −3009.62% |
| Q3 2025 | 2025-09-30 | −$899,000 | $8.0M | — | −17980.00% |
| Q2 2025 | 2025-06-30 | −$1.2M | $10.5M | — | −19766.67% |
| Q1 2025 | 2025-03-31 | −$1.6M | $11.6M | — | −19837.50% |
| Q4 2024 | 2024-12-31 | $90,000 | $12.1M | — | +900.00% |
| Q3 2024 | 2024-09-30 | −$8.9M | $2.2M | — | −892.47% |
| Q2 2024 | 2024-06-30 | −$11.7M | $1.1M | — | −1190.91% |
| Q1 2024 | 2024-03-31 | −$13.2M | $3.2M | — | −1302.08% |
| Q4 2023 | 2023-12-31 | −$12.1M | $5.1M | — | −1149.38% |
| Q3 2023 | 2023-09-30 | −$11.1M | $8.6M | — | −1404.17% |
| Q2 2023 | 2023-06-30 | −$12.7M | $10.2M | — | −7666.27% |
| Q1 2023 | 2023-03-31 | −$16.4M | −$3.6M | — | −3674.44% |
| Q4 2022 | 2022-12-31 | −$17.1M | $933,000 | — | −15286.61% |
| Q3 2022 | 2022-09-30 | −$19.7M | −$11.6M | — | −25864.47% |
| Q2 2022 | 2022-06-30 | −$22.9M | −$16.2M | — | — |
| Q1 2022 | 2022-03-31 | −$12.8M | −$3.6M | — | −6792.06% |
| Q4 2021 | 2021-12-31 | −$18.1M | −$11.3M | — | — |
| Q3 2021 | 2021-09-30 | −$8.1M | −$2.2M | — | −4026.50% |
| Q2 2021 | 2021-06-30 | −$6.7M | −$1.2M | — | — |
| Q1 2021 | 2021-03-31 | −$9.2M | −$5.4M | — | — |
| Q4 2020 | 2020-12-31 | −$6.7M | −$2.6M | — | — |
| Q3 2020 | 2020-09-30 | −$5.8M | −$3.0M | — | — |
| Q2 2020 | 2020-06-30 | −$5.6M | −$3.1M | — | — |
| Q1 2020 | 2020-03-31 | −$3.8M | $80,000 | — | — |
| Q4 2019 | 2019-12-31 | −$4.1M | −$2.5M | — | — |
| Q3 2019 | 2019-09-30 | −$2.9M | −$505,577 | — | — |
| Q2 2019 | 2019-06-30 | −$2.5M | −$1.7M | — | — |
| Q1 2019 | 2019-03-31 | −$3.9M | −$2.0M | — | — |
| Q4 2017 | 2017-12-31 | −$1.6M | −$384,104 | — | — |
| Q3 2017 | 2017-09-30 | −$2.4M | −$1.1M | — | — |
| Q2 2017 | 2017-06-30 | −$823,604 | $684,665 | — | — |
| Q1 2017 | 2017-03-31 | −$1.8M | −$1.3M | — | — |
| Q4 2016 | 2016-12-31 | −$1.2M | — | — | — |
| Q3 2016 | 2016-09-30 | −$1.2M | — | — | — |
| Q2 2016 | 2016-06-30 | −$1.5M | — | — | — |
| Q1 2016 | 2016-03-31 | −$531,216 | — | — | — |
PAVmed free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$22.0M to −$5.2M, a net increase of $16.7M. PAVmed's latest reported quarter, Q2 2026, generated −$2.7M in free cash flow, a decrease of $1.5M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review PAVmed filings at SEC.gov ↗